Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash to Debt 1.61
BIO's Cash to Debt is ranked higher than
65% of the 258 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.79 vs. BIO: 1.61 )
BIO' s 10-Year Cash to Debt Range
Min: 0.04   Max: 1.61
Current: 1.61

0.04
1.61
Equity to Asset 0.64
BIO's Equity to Asset is ranked higher than
72% of the 240 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.64 vs. BIO: 0.64 )
BIO' s 10-Year Equity to Asset Range
Min: 0.33   Max: 0.67
Current: 0.64

0.33
0.67
Interest Coverage 2.77
BIO's Interest Coverage is ranked lower than
53% of the 146 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 62.48 vs. BIO: 2.77 )
BIO' s 10-Year Interest Coverage Range
Min: 2.18   Max: 22.17
Current: 2.77

2.18
22.17
F-Score: 4
Z-Score: 3.67
M-Score: -2.86
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 6/10

vs
industry
vs
history
Operating margin (%) 6.96
BIO's Operating margin (%) is ranked higher than
81% of the 255 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.61 vs. BIO: 6.96 )
BIO' s 10-Year Operating margin (%) Range
Min: 6.23   Max: 15.98
Current: 6.96

6.23
15.98
Net-margin (%) 3.67
BIO's Net-margin (%) is ranked higher than
79% of the 255 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.20 vs. BIO: 3.67 )
BIO' s 10-Year Net-margin (%) Range
Min: 2.11   Max: 9.63
Current: 3.67

2.11
9.63
ROE (%) 3.64
BIO's ROE (%) is ranked higher than
76% of the 232 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.08 vs. BIO: 3.64 )
BIO' s 10-Year ROE (%) Range
Min: 3.7   Max: 20.35
Current: 3.64

3.7
20.35
ROA (%) 2.36
BIO's ROA (%) is ranked higher than
78% of the 260 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -0.22 vs. BIO: 2.36 )
BIO' s 10-Year ROA (%) Range
Min: 2.26   Max: 9.66
Current: 2.36

2.26
9.66
ROC (Joel Greenblatt) (%) 14.32
BIO's ROC (Joel Greenblatt) (%) is ranked higher than
79% of the 259 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.02 vs. BIO: 14.32 )
BIO' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: 13.54   Max: 43.08
Current: 14.32

13.54
43.08
Revenue Growth (3Y)(%) 2.50
BIO's Revenue Growth (3Y)(%) is ranked higher than
69% of the 193 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 5.40 vs. BIO: 2.50 )
BIO' s 10-Year Revenue Growth (3Y)(%) Range
Min: 2.5   Max: 21
Current: 2.5

2.5
21
EBITDA Growth (3Y)(%) -7.40
BIO's EBITDA Growth (3Y)(%) is ranked higher than
69% of the 169 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.10 vs. BIO: -7.40 )
BIO' s 10-Year EBITDA Growth (3Y)(%) Range
Min: -7.4   Max: 40.3
Current: -7.4

-7.4
40.3
EPS Growth (3Y)(%) -25.80
BIO's EPS Growth (3Y)(%) is ranked higher than
62% of the 172 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -2.30 vs. BIO: -25.80 )
BIO' s 10-Year EPS Growth (3Y)(%) Range
Min: -25.8   Max: 76.3
Current: -25.8

-25.8
76.3
» BIO's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q4 2013

BIO Guru Trades in Q4 2013

NWQ Managers 331,811 sh (+1376.49%)
Paul Tudor Jones 7,445 sh (+61.85%)
John Rogers 1,102,607 sh (+0.55%)
Mario Gabelli 97,400 sh (+0.41%)
Private Capital 16,452 sh (unchged)
Pioneer Investments 62,472 sh (unchged)
Ken Fisher 344,861 sh (-2.28%)
Chuck Royce 1,069,182 sh (-8.3%)
First Pacific Advisors 228,300 sh (-24.83%)
Jim Simons 28,900 sh (-59.69%)
» More
Q1 2014

BIO Guru Trades in Q1 2014

John Burbank 4,652 sh (New)
NWQ Managers 433,899 sh (+30.77%)
Jim Simons 29,770 sh (+3.01%)
Private Capital 16,452 sh (unchged)
First Pacific Advisors 225,400 sh (-1.27%)
Ken Fisher 337,141 sh (-2.24%)
Mario Gabelli 94,600 sh (-2.87%)
John Rogers 1,024,729 sh (-7.06%)
Pioneer Investments 51,310 sh (-17.87%)
Chuck Royce 872,870 sh (-18.36%)
Paul Tudor Jones 5,650 sh (-24.11%)
» More
Q2 2014

BIO Guru Trades in Q2 2014

Jim Simons 61,500 sh (+106.58%)
NWQ Managers 523,806 sh (+20.72%)
Paul Tudor Jones 5,950 sh (+5.31%)
First Pacific Advisors 225,400 sh (unchged)
Pioneer Investments 51,310 sh (unchged)
John Burbank Sold Out
Mario Gabelli 93,200 sh (-1.48%)
Private Capital 16,052 sh (-2.43%)
John Rogers 983,452 sh (-4.03%)
Chuck Royce 812,845 sh (-6.88%)
Ken Fisher 294,741 sh (-12.58%)
» More
Q3 2014

BIO Guru Trades in Q3 2014

Joel Greenblatt 4,212 sh (New)
Paul Tudor Jones 8,014 sh (+34.69%)
Jim Simons 74,500 sh (+21.14%)
John Rogers 1,067,226 sh (+8.52%)
NWQ Managers 526,106 sh (+0.44%)
First Pacific Advisors 225,400 sh (unchged)
Pioneer Investments 51,310 sh (unchged)
Ken Fisher 293,171 sh (-0.53%)
Mario Gabelli 89,900 sh (-3.54%)
Private Capital 15,187 sh (-5.39%)
Chuck Royce 663,390 sh (-18.39%)
» More
» Details

Insider Trades

Latest Guru Trades with BIO

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
John Rogers 2014-09-30 Add 8.52%0.13%$114.72 - $121.81 $ 121.312%1067226
Joel Greenblatt 2014-09-30 New Buy$114.72 - $121.81 $ 121.312%4212
NWQ Managers 2014-06-30 Add 20.72%0.11%$118.68 - $129.7 $ 121.31-1%523806
John Burbank 2014-06-30 Sold Out 0.02%$118.68 - $129.7 $ 121.31-1%0
John Rogers 2014-03-31 Reduce -7.06%0.12%$121.07 - $133.73 $ 121.31-5%1024729
NWQ Managers 2014-03-31 Add 30.77%0.12%$121.07 - $133.73 $ 121.31-5%433899
John Burbank 2014-03-31 New Buy0.02%$121.07 - $133.73 $ 121.31-5%4652
NWQ Managers 2013-12-31 Add 1376.49%0.34%$115.53 - $124.5 $ 121.310%331811
John Rogers 2013-09-30 Add 8.32%0.15%$112.74 - $125.8 $ 121.313%1096613
NWQ Managers 2013-09-30 New Buy0.03%$112.74 - $125.8 $ 121.313%22473
Private Capital 2013-03-31 Reduce -22.47%0.05%$105.05 - $126 $ 121.313%16887
Joel Greenblatt 2013-03-31 Sold Out 0.04%$105.05 - $126 $ 121.313%0
Joel Greenblatt 2012-12-31 Reduce -65.94%0.09%$100.02 - $109.55 $ 121.3117%6350
George Soros 2012-09-30 Sold Out 0.02%$92.4 - $109.42 $ 121.3120%0
Mario Gabelli 2012-06-30 Add 2335.14%0.07%$95.57 - $116 $ 121.3118%90100
George Soros 2012-06-30 New Buy0.02%$95.57 - $116 $ 121.3118%15000
Joel Greenblatt 2012-03-31 Add 56.04%0.07%$96.64 - $105.67 $ 121.3128%22134
Joel Greenblatt 2011-12-31 New Buy0.16%$88.92 - $102.55 $ 121.3127%14185
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Top Ranked Articles about Bio-Rad Laboratories Inc

Widely Held Guru Stocks Near Historical Low P/B Ratios
Buying stocks at historically low price-to-book (P/B) ratios has been an effective strategy. The model portfolio, “Top 25 Historical Low P/B Ratio Companies”, has outperformed the S&P 500 by 29.51 percent since its inception in 2010. The following stocks are widely held by the investing gurus we follow and are trading near their historical low P/B ratios: Read more...
Guru Held Stocks Near Historical Low P/B
Buying stocks at historically low price-to-book (P/B) ratios has been an effective strategy. The model portfolio, “Top 25 Historical Low P/B Ratio Companies”, has outperformed the S&P 500 by 25.44 percent since its inception in 2010. The following stocks are the most widely held stocks by the investing gurus we follow that are trading near their historical low P/B ratios: Read more...
Morning Coffee: Widely Held Guru Stocks Near Historical Low P/B
Morning Coffee: Widely Held Guru Stocks Near Historical Low P/B Read more...
Morning Coffee: Widely Held Guru Stocks Near Historical Low P/B
This morning we are going to take a look at stocks that are widely held by the gurus and trading near their historical low price-to-book ratios (P/B): Read more...
Morning Coffee: Widely Held Guru Stocks Near Historical Low P/B
This morning we are going to take a look at stocks that are widely held by the gurus and trading near historical low price-to-book (P/B) ratios: Read more...
Morning Coffee: Widely Held Guru Stocks Near Historic Low P/B
This morning we are going to take a look at stocks that are widely held by the gurus and trading near historic low price-to-book ratios (P/B): Read more...
Morning Coffee: Widely Held Guru Stocks Near Historical Low P/B
This morning we are going to take a look at stocks that are widely held by the gurus and trading near historical low price-to-book ratios (P/B): Read more...
Morning Coffee: Widely Held Guru Stocks Near Historical Low P/B
This morning we will take a look at companies that are widely held by the gurus and trading near historical low price-to-book (P/B) ratios. Read more...

Ratios

vs
industry
vs
history
P/E(ttm) 44.10
BIO's P/E(ttm) is ranked higher than
83% of the 281 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9999.00 vs. BIO: 44.10 )
BIO' s 10-Year P/E(ttm) Range
Min: 13.68   Max: 58.63
Current: 44.1

13.68
58.63
P/B 1.61
BIO's P/B is ranked higher than
94% of the 281 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.37 vs. BIO: 1.61 )
BIO' s 10-Year P/B Range
Min: 1.44   Max: 3.22
Current: 1.61

1.44
3.22
P/S 1.62
BIO's P/S is ranked higher than
85% of the 281 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.06 vs. BIO: 1.62 )
BIO' s 10-Year P/S Range
Min: 0.87   Max: 2.15
Current: 1.62

0.87
2.15
PFCF 19.66
BIO's PFCF is ranked higher than
93% of the 281 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9999.00 vs. BIO: 19.66 )
BIO' s 10-Year PFCF Range
Min: 9.63   Max: 475.33
Current: 19.66

9.63
475.33
EV-to-EBIT 21.41
BIO's EV-to-EBIT is ranked higher than
86% of the 281 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9999.00 vs. BIO: 21.41 )
BIO' s 10-Year EV-to-EBIT Range
Min: 8.3   Max: 23.1
Current: 21.41

8.3
23.1
Shiller P/E 24.84
BIO's Shiller P/E is ranked higher than
94% of the 281 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9999.00 vs. BIO: 24.84 )
BIO' s 10-Year Shiller P/E Range
Min: 16.36   Max: 35.92
Current: 24.84

16.36
35.92
Current Ratio 3.50
BIO's Current Ratio is ranked higher than
78% of the 256 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.56 vs. BIO: 3.50 )
BIO' s 10-Year Current Ratio Range
Min: 1.87   Max: 4.52
Current: 3.5

1.87
4.52
Quick Ratio 2.48
BIO's Quick Ratio is ranked higher than
75% of the 256 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.14 vs. BIO: 2.48 )
BIO' s 10-Year Quick Ratio Range
Min: 1.16   Max: 3.45
Current: 2.48

1.16
3.45

Valuation & Return

vs
industry
vs
history
Price/Net Current Asset Value 205.61
BIO's Price/Net Current Asset Value is ranked higher than
77% of the 281 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9999.00 vs. BIO: 205.61 )
BIO' s 10-Year Price/Net Current Asset Value Range
Min: 17.15   Max: 2402.8
Current: 205.61

17.15
2402.8
Price/Tangible Book 2.52
BIO's Price/Tangible Book is ranked higher than
89% of the 281 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 7.74 vs. BIO: 2.52 )
BIO' s 10-Year Price/Tangible Book Range
Min: 1.11   Max: 6.43
Current: 2.52

1.11
6.43
Price/DCF (Projected) 1.11
BIO's Price/DCF (Projected) is ranked higher than
96% of the 281 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9999.00 vs. BIO: 1.11 )
BIO' s 10-Year Price/DCF (Projected) Range
Min: 0.78   Max: 17.2
Current: 1.11

0.78
17.2
Price/Median PS Value 1.08
BIO's Price/Median PS Value is ranked higher than
79% of the 281 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.32 vs. BIO: 1.08 )
BIO' s 10-Year Price/Median PS Value Range
Min: 0.25   Max: 1.3
Current: 1.08

0.25
1.3
Price/Graham Number 2.22
BIO's Price/Graham Number is ranked higher than
92% of the 281 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9999.00 vs. BIO: 2.22 )
BIO' s 10-Year Price/Graham Number Range
Min: 0.68   Max: 3.45
Current: 2.22

0.68
3.45
Earnings Yield (Greenblatt) 4.70
BIO's Earnings Yield (Greenblatt) is ranked higher than
86% of the 253 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.40 vs. BIO: 4.70 )
BIO' s 10-Year Earnings Yield (Greenblatt) Range
Min: 4.3   Max: 12
Current: 4.7

4.3
12
Forward Rate of Return (Yacktman) -0.05
BIO's Forward Rate of Return (Yacktman) is ranked higher than
59% of the 111 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 11.35 vs. BIO: -0.05 )
BIO' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -0.1   Max: 28.8
Current: -0.05

-0.1
28.8

Business Description

Industry: Medical Diagnostics & Research » Diagnostics & Research
Compare:A, ROP, GRMN, HXGBY, TRMB » details
Traded in other countries:BUWA.Germany,
Bio-Rad Laboratories Inc was founded in 1952 and incorporated in 1957. The Company manufactures and supplies the life science research, healthcare, analytical chemistry and other markets with a range of products and systems used to separate complex chemical and biological materials and to identify, analyze and purify their components. It operates in two industry segments designated as Life Science and Clinical Diagnostics. Both segments operate worldwide. Life science is the study of the characteristics, behavior, and structure of living organisms and their component systems. Life Science segment is at the forefront of discovery, creating advanced tools to answer complex biological questions. The Company is engaged in developing, manufacturing and marketing a range of more than 5,000 reagents, apparatus and laboratory instruments that serve a global customer base. Many of its products are used in established research techniques, biopharmaceutical production processes and food testing regimes. These techniques are typically used to separate, purify and identify biological materials such as proteins, nucleic acids and bacteria within a laboratory or production setting. Its main life science customers include universities and medical schools, industrial research organizations, government agencies, pharmaceutical manufacturers, biotechnology researchers, food producers and food testing laboratories. Clinical Diagnostics segment designs, manufactures, sells and supports test systems, informatics systems, test kits and specialized quality controls that serve clinical laboratories in the global diagnostics market. Its products currently address specific niches within the in vitro diagnostics (IVD) test market. It supplies more than 3,000 different products that cover more than 300 clinical diagnostic tests to the IVD test market. IVD tests are conducted outside the human body and are used to identify and measure substances in a patient's tissue, blood or urine. Its products consist of reagents, instruments and software, typically provided to its customers as an integrated package to allow them to generate reproducible test results. Its main clinical diagnostic customers include hospital laboratories, reference laboratories, transfusion laboratories and physician office laboratories. The Company owns numerous U.S. and international patents and patent licenses. Each of the Company's segments maintains a sales force to sell its products on a direct basis. Major competitors in the clinical diagnostic segment include Roche, Abbott Laboratories (Diagnostic Division), Siemens Medical Diagnostics Solutions (formerly Dade-Behring, Diagnostics Products Corporation, and Bayer Diagnostics), Beckman Coulter, Becton-Dickinson, bioMérieux, Johnson & Johnson (Ortho Clinical Diagnostics), Thermo Fisher, Tosoh, Immucor, Cepheid, and DiaSorin. The Company's operations are subject to federal, state, local and foreign environmental laws and regulations tha
» More Articles for BIO

Headlines

Articles On GuruFocus.com
Bio-Rad Laboratories Resolves Foreign Corrupt Practices Act Matters With U.S. Government Nov 03 2014 
Bio-Rad to Report Third-Quarter 2014 Financial Results Tuesday, November 4, 2014 Oct 15 2014 
Bio-Rad Appoints John Goetz as Chief Operating Officer and Announces Other Executive Appointments Oct 15 2014 
Widely Held Guru Stocks Near Historical Low P/B Ratios Aug 11 2014 
Guru Held Stocks Near Historical Low P/B Jul 22 2014 
Morning Coffee: Widely Held Guru Stocks Near Historical Low P/B Jun 02 2014 
Morning Coffee: Widely Held Guru Stocks Near Historical Low P/B May 27 2014 
Morning Coffee: Widely Held Guru Stocks Near Historical Low P/B May 19 2014 
Morning Coffee: Widely Held Guru Stocks Near Historic Low P/B May 12 2014 
Morning Coffee: Widely Held Guru Stocks Near Historical Low P/B Apr 23 2014 

More From Other Websites
Bio-Rad Receives Premarket Application Approval for Its Geenius HIV 1/2 Supplemental Assay Nov 18 2014
BIO RAD LABORATORIES INC Financials Nov 14 2014
Corruption Currents: Chinese Hackers Breach U.S. Weather Network Nov 13 2014
SHAREHOLDER ALERT: The Law Firm of Levi & Korsinsky, LLP Launches an Investigation into Possible... Nov 12 2014
Corruption Currents: Judge Extends Kabul Bank Execs' Sentences Nov 12 2014
Lifshitz & Miller Law Firm Announces Investigation of Barrett Business Services, Inc., Bio-Rad... Nov 11 2014
10-Q for Bio-Rad Laboratories, Inc. Nov 09 2014
SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Announces an Investigation into Possible Breaches of... Nov 07 2014
BIO RAD LABORATORIES INC Files SEC form 10-Q, Quarterly Report Nov 07 2014
Corruption Currents: Lawyers Can Play Role as Unwitting Launderers Nov 06 2014
Ryan & Maniskas, LLP Announces Investigation of Bio-Rad Laboratories, Inc. Nov 05 2014
BIO-RAD INVESTIGATION INITIATED BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC... Nov 05 2014
Bio-Rad Reports Third-Quarter 2014 Financial Results Nov 04 2014
Bio-Rad posts 3Q profit Nov 04 2014
Bio-Rad posts 3Q profit Nov 04 2014
SHAREHOLDER ALERT: The Law Firm of Levi & Korsinsky, LLP Launches an Investigation into Possible... Nov 04 2014
Faruqi & Faruqi, LLP is Investigating Bio-Rad Laboratories, Inc. (BIO) on Behalf of its Shareholders Nov 04 2014
Robbins Arroyo LLP Is Investigating the Officers and Directors of Bio-Rad Laboratories, Inc. (BIO)... Nov 04 2014
BIO RAD LABORATORIES INC Files SEC form 8-K, Results of Operations and Financial Condition,... Nov 04 2014
Bio-Rad Reports Third-Quarter 2014 Financial Results Nov 04 2014

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK